Immune-Mediated Diseases Following COVID-19 Vaccination: Report of a Teaching Hospital-Based Case-Series
Open Access
- 16 December 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (24), 7484
- https://doi.org/10.3390/jcm11247484
Abstract
The occurrence and course of immune-mediated diseases (IMDs) following COVID-19 vaccination has been little explored so far. We retrieved, among adult patients hospitalized at the Internal Department of a French university hospital up to May 2022, all those who had developed, or relapsed to, an IMD less than 3 weeks following COVID-19 vaccination, without other triggers. Twenty-seven (24 new-onset) post-COVID-19 vaccine IMDs were recorded. They comprised giant cell arteritis or polymyalgia rheumatica (n = 16, HLA-DRB1*04 in 58% of 12 assessed GCA cases), immune-mediated necrotizing myositis or acute rhabdomyolysis, systemic vasculitis, immune thrombocytopenic purpura, rheumatoid arthritis, anti-synthetase syndrome, and adult-onset Still’s disease. The causative vaccines were mRNA-based (20 cases) or viral vector-based (7 cases). The IMD typically occurred after the first vaccine dose, with an average delay of 8 (5 SD) days. The patients’ mean age was 67 years, and 58% were women. The IMDs had protracted courses in all but three of the patients and typically required high-dose glucocorticoids, in combination with immunomodulators in 13 patients. One patient died of intractable rhabdomyolysis, whereas five suffered permanent damage from IMDs. Eleven patients with well-controlled IMDs completed their COVID-19 vaccination schedule, and two suffered mild IMD relapses. There is a risk of IMDs, notably GCA/PMR, and muscle disorders, following COVID-19 vaccination. Such adverse reactions typically occurred after the first dose, raising concern about subsequent COVID-19 vaccinations. However, early re-challenge in well-controlled IMDs appeared safe.This publication has 66 references indexed in Scilit:
- Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported casesImmunologic Research, 2014
- A review on the association between inflammatory myopathies and vaccinationAutoimmunity Reviews, 2014
- Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspectsJournal of Autoimmunity, 2013
- 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiativeAnnals Of The Rheumatic Diseases, 2012
- Vaccines as a trigger for myopathiesLupus, 2009
- Toll-like receptors in giant cell arteritisClinical Immunology, 2005
- Rheumatoid vasculitis following influenza vaccinationRheumatology, 2003
- The American College of Rheumatology 1990 criteria for the classification of giant cell arteritisArthritis & Rheumatism, 1990
- The American College of Rheumatology 1990 criteria for the classification of henoch‐schönlein purpuraArthritis & Rheumatism, 1990